Cargando…
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
TL1A is an attractive therapeutic target for the treatment of mucosal inflammation associated with inflammatory bowel disease (IBD) and asthma. Blockade of the TL1A pathway has been shown to reduce inflammatory responses while leaving baseline immunity intact, and to be beneficial in animal models o...
Autores principales: | Clarke, Adam W., Poulton, Lynn, Shim, Doris, Mabon, David, Butt, Danyal, Pollard, Matthew, Pande, Vanya, Husten, Jean, Lyons, Jacquelyn, Tian, Chen, Doyle, Anthony G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973687/ https://www.ncbi.nlm.nih.gov/pubmed/29436901 http://dx.doi.org/10.1080/19420862.2018.1440164 |
Ejemplares similares
-
Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model
por: Nambiar, Jonathan, et al.
Publicado: (2015) -
Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab
por: Liddament, Mark, et al.
Publicado: (2018) -
Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA TL+ and TL- strains
Publicado: (1985) -
Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease
por: Richard, Arianne C., et al.
Publicado: (2018) -
ANTIGENIC MODULATION : LOSS OF TL ANTIGEN FROM CELLS EXPOSED TO TL ANTIBODY. STUDY OF THE PHENOMENON IN VITRO
por: Old, Lloyd J., et al.
Publicado: (1968)